# A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

> **NCT04439890** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 369 (estimated)

## Conditions studied

- Advanced Non-squamous Cell Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib hydrochloride capsule
- **DRUG:** Carboplatin injection
- **DRUG:** Pemetrexed disodium f Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04439890
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-08
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 369 (ESTIMATED)
- **Last updated:** 2020-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439890, "A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04439890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*